MedTrace Logo

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

NCT06361329 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-02-17

No results posted yet for this study

Summary

ETP-ALL is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) with poor outcomes and prognosis. Effective induction therapy is crucial in improving the treatment effect. Based on our laboratory research and clinical practice, the venetoclax plus HAG regimen shows promising efficacy in treating ETP-ALL. Therefore, we plan to conduct a prospective, multicenter Phase III clinical study to evaluate the efficacy of the venetoclax plus HAG regimen in treating newly diagnosed ETP-ALL patients.

Conditions

  • ETP-ALL

Interventions

DRUG

Homoharringtonine

Intravenous infusion

DRUG

venetoclax

Orally by mouth

DRUG

Cytarabine

subcutaneous injection or Intravenous infusion

DRUG

G-CSF

subcutaneous injection

DRUG

Vindesine

Intravenous infusion

DRUG

Daunorubicin

Intravenous infusion

DRUG

cyclophosphamide

Intravenous infusion

DRUG

Dexamethasone

Intravenous infusion or orally

DRUG

L-ASP

subcutaneous injection

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-03
Primary Completion
2026-03-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06361329 on ClinicalTrials.gov